Current Provider-Administered Drug Policies - Blue Advantage
Note: Coverage is subject to the member's specific benefits. Group-specific policies will supersede these policies when applicable. Please refer to the member's benefit plan.
Blue Advantage Part B Provider-Administered Drug Precertification Program (Effective August 1, 2023)
Precertification through Magellan Rx is required for the provider-administered drugs on the following list when administered in a provider's office, outpatient facility or home health setting. Treatments indicated as gene therapy/cellular immunotherapy require precertification when administered in any place of treatment.
Patients receiving medication on the precertification drug list prior to August 1, 2023, have an authorization in our system through December 31, 2023, for continued claims payment. On January 1, 2024, continued coverage will require valid precertification through Magellan Rx.
How to submit a precertification request to Magellan Rx
Refer to the member's eligibility and benefits to initiate or check the status of a pre-service review.
Magellan Rx Management℠ is an independent company providing medical review services on behalf of Blue Cross and Blue Shield of Alabama.
Blue Advantage Part B Provider-Administered Drug Policies
Clicking the links below will take you away from our website to other sites. These sites are not the responsibility of or under the control of Blue Cross and Blue Shield of Alabama.
National Coverage Determinations
Refer to the following to search for National Coverage Determinations:
Local Coverage Determinations
For Local Coverage Determinations, refer to the following sites:
Reasonable and Necessary Guidelines
In the absence of a National Coverage Determination, Local Coverage Determination or CMS Manual Instruction, reasonable and necessary guidelines still apply.
Refer to the original Medicare manual Pub. 100-02, Chapter 15, Sec. 50 Drugs and Biologicals.